EUVIMEDEUVIMED entdecken
Crossref

High-dose carbidopa achieves sustained levodopa pharmacokinetics and efficacy in Parkinson’s disease models

Akane Hayashi iD, Atsushi Hosomi iD, Shinichi Uchida iD, Junichi Enokizono iD

Journal of Pharmacy and Pharmacology · 2025

DOI: 10.1093/jpp/rgaf118 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Pharmacy and Pharmacology, 2025. Verfasst von Akane Hayashi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Research Division, Research Planning Department, Research Management Office, Kyowa Kirin, Tokyo 100-0004, Japan. Hauptthemen laut MEDLINE: Carbidopa, Levodopa, Antiparkinson Agents, Parkinson Disease. Die Arbeit nennt 27 Literaturangaben. Gefördert von: Kyowa Kirin Co., Ltd.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To evaluate the impact of supraclinical doses of carbidopa on the pharmacokinetics and pharmacodynamics of levodopa in rat and monkey models of Parkinson’s disease and to assess the causes for the insufficiency of dihydroxyphenylalanine (DOPA) decarboxylase inhibition at the clinical dose of carbidopa.

Methods

The effects of supraclinical doses of carbidopa and entacapone, a catechol-O-methyltransferase inhibitor, were compared with those of equivalent clinical doses in Parkinson’s disease models. Pharmacological assessments were conducted using 6-hydroxydopamine-lesioned rats and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmosets. DOPA decarboxylase levels in the human liver, human kidney, and rat liver were quantified. Key findings Supraclinical doses of carbidopa extended the plasma half-life of levodopa in rats, whereas high-dose entacapone did not. Prolonged and sustained pharmacological effects of levodopa were observed in both Parkinson’s disease models with supraclinical doses of carbidopa (80-fold and 200-fold greater than the clinical equivalent in rats and marmosets, respectively). DOPA decarboxylase levels in the human liver, human kidney, and rat liver were estimated to be in the submicromolar range, comparable to or exceeding plasma carbidopa concentrations at the clinical dose.

Conclusion

High-dose carbidopa co-administration is a promising approach to achieve sustained clinical efficacy of levodopa while mitigating the risk of motor complications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CarbidopaLevodopaAntiparkinson AgentsParkinson DiseaseAnimalsRatsHumansCatecholsMaleDisease Models, AnimalCatechol O-Methyltransferase InhibitorsCallithrixNitrilesHalf-LifeDopa DecarboxylaseRats, Sprague-DawleyLiverDose-Response Relationship, DrugOxidopamineFemale

Stichwörter der Autor:innen

Parkinson’s diseasecombination therapycontinuous dopamine stimulationhigh-dose carbidopalevodopa

Substanzen

CarbidopaLevodopaAntiparkinson AgentsentacaponeCatecholsCatechol O-Methyltransferase InhibitorsNitrilesDopa DecarboxylaseOxidopamine

Autor:innen und Institutionen

  • Research Division, Research Planning Department, Research Management Office, Kyowa Kirin, Tokyo 100-0004, Japan.
  • Pharmacokinetics Research Laboratories, Research Unit, Research Division, Kyowa Kirin, Shizuoka 411-0943, Japan.
  • Biomedical Science Research Laboratories 1, Research Unit, Research Division, Kyowa Kirin, Shizuoka 411-0943, Japan.
  • Development Division, Medical Pharmacology Department, Kyowa Kirin, Tokyo 100-0004, Japan.

ORCID-Profile: Akane Hayashi, Atsushi Hosomi, Shinichi Uchida, Junichi Enokizono

Förderung

  • Kyowa Kirin Co., Ltd

Zitieren

APA

Hayashi, A., Hosomi, A., Uchida, S., & Enokizono, J. (2025). High-dose carbidopa achieves sustained levodopa pharmacokinetics and efficacy in Parkinson’s disease models. Journal of Pharmacy and Pharmacology. https://doi.org/10.1093/jpp/rgaf118

Vancouver

Hayashi A, Hosomi A, Uchida S, Enokizono J. High-dose carbidopa achieves sustained levodopa pharmacokinetics and efficacy in Parkinson’s disease models. Journal of Pharmacy and Pharmacology. 2025. doi:10.1093/jpp/rgaf118

BibTeX
@article{Hayashi2025,
  author = {Hayashi, Akane and Hosomi, Atsushi and Uchida, Shinichi and Enokizono, Junichi},
  title = {High-dose carbidopa achieves sustained levodopa pharmacokinetics and efficacy in Parkinson’s disease models},
  journal = {Journal of Pharmacy and Pharmacology},
  year = {2025},
  doi = {10.1093/jpp/rgaf118}
}
Kostenlos starten →